ID: ALA3754102

Max Phase: Preclinical

Molecular Formula: C30H49NO3

Molecular Weight: 471.73

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC1(C)CC[C@]2(C(=O)NO)CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1

Standard InChI:  InChI=1S/C30H49NO3/c1-25(2)14-16-30(24(33)31-34)17-15-28(6)19(20(30)18-25)8-9-22-27(5)12-11-23(32)26(3,4)21(27)10-13-29(22,28)7/h8,20-23,32,34H,9-18H2,1-7H3,(H,31,33)/t20-,21-,22+,23-,27-,28+,29+,30-/m0/s1

Standard InChI Key:  GZSHDELCJRZSTQ-GTOFXWBISA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 471.73

Molecular Weight (Monoisotopic): 471.3712

AlogP: 6.65

#Rotatable Bonds: 1

Polar Surface Area: 69.56

Molecular Species: NEUTRAL

HBA: 3

HBD: 3

#RO5 Violations: 1

HBA (Lipinski): 4

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 8.83

CX Basic pKa:

CX LogP: 5.78

CX LogD: 5.77

Aromatic Rings: 0

Heavy Atoms: 34

QED Weighted: 0.23

Np Likeness Score: 2.89

References

1. Wiemann J, Heller L, Csuk R..  (2016)  Targeting cancer cells with oleanolic and ursolic acid derived hydroxamates.,  26  (3): [PMID:26750249] [10.1016/j.bmcl.2015.12.064]

2. Minassi A, Rogati F, Cruz C, Prados ME, Galera N, Jinénez C, Appendino G, Bellido ML, Calzado MA, Caprioglio D, Muñoz E..  (2018)  Triterpenoid Hydroxamates as HIF Prolyl Hydrolase Inhibitors.,  81  (10): [PMID:30350996] [10.1021/acs.jnatprod.8b00514]

Source

Source(1):

• Scientific Literature